Comparison of Intratympanic Oxytocin and Dexamethasone in Cisplatin Ototoxicity: An Experimental Study

• Published in: Indian journal of otolaryngology, and head, and neck surgery Vol. 76; no. 4; pp. 3405 - 3411
• Main Authors: Taş, Burak Mustafa, Özel, Gökçe, Azman, Musa, Çakmak Karaer, Işıl, Kılıç, Rahmi
• Format: Journal Article
• Language: English
• Published: New Delhi Springer India 01.08.2024; Springer Nature B.V
• Subjects: Head and Neck Surgery; Hormones; Medicine; Medicine & Public Health; Original Article; Otorhinolaryngology; Atosiban; Dexamethasone; Oxytocin; Cisplatin; Ototoxicity
• ISSN: 2231-3796; 0973-7707
• DOI: 10.1007/s12070-024-04701-z

Although it is widely used, there is still no valid treatment for ototoxicity caused by the antineoplastic drug cisplatin. In this study, we aimed to investigate the efficacy of intratympanic resveratrol and intratympanic dexamethasone treatment in cisplatin-induced ototoxicity. We also compared intratympanic atosiban (oxytocin antagonist) and oxytocin in cisplatin ototoxicity. In this study, 30 rats (60 ears) were used by separating into 5 groups. Cisplatin, oxytocin, dexamethasone, atosiban and 0.9% NaCl were administered intraperitoneally to all groups separately. Auditory Brainstem Response and Distortion Product Otoacoustic Emission tests were performed on all groups before and 72 h after the procedure. Pre-treatment values were higher than post-treatment values in all groups ( p  < 0.001). There was no significant prolongation of the post-treatment Auditory Brainstem Response I-IV interval in the oxytocin and dexamethasone groups ( p  > 0.05). There was no significant decrease in the frequencies of 2832 and 4004 after treatment in the oxytocin and dexamethasone group compared to pre-treatment in Distortion Product Otoacoustic Emission. As a result, it has been shown that intratympanic oxytocin may be an option that can be used in the treatment, although it is not as effective as dexamethasone in preventing cisplatin ototoxicity.